REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Results & Progress
13

Real Results from DSIP — No Hype

Cedar Burton·about 1 month ago
No hype, just facts from my DSIP experience. Too many posts online read like advertisements, so here is a neutral perspective. I ran DSIP for 10 weeks. The first two weeks were a waste from an effects standpoint but necessary for establishing tolerance. Real noticeable effects started around week 3-4. The standout result for me was joint health. I have had chronic elbow tendinopathy for over a year and it improved by roughly 60-70 percent during my protocol. This alone justified the experiment. I was able to return to exercises I had been avoiding for months. Other effects were modest: slightly better sleep, slightly faster recovery from training. Nothing dramatic but consistently present. I did not experience the dramatic body composition changes some people report. My weight stayed essentially the same. I suspect those claims are either exaggerated or confounded by simultaneous diet and training changes. Cost-benefit analysis: for me it was worth it primarily for the joint benefits. If those had not materialized, the other effects alone probably would not have justified the cost and inconvenience of daily injections.

Comments (5)

Darcy CareyDEMO·about 1 month ago

Great write-up. I have been running a similar DSIP protocol and my experience aligns pretty closely with what you described. The sleep improvements were the first thing I noticed too, usually around week 2-3. One thing I would add is that I found keeping injection sites consistent with rotation between 4-5 spots worked better than random placement. Less irritation overall.

2
Zev GrossDEMO·about 1 month ago

This matches my experience with DSIP almost exactly. The timeline you describe — subtle at first, then clearly noticeable by week 4-5 — is very typical from what I have seen across multiple reports. For anyone reading this and feeling impatient in the first couple weeks, stick with it. The effects are cumulative and take time to establish.

3
Marley DavidsonDEMO·about 1 month ago

Appreciate the honest assessment. Too many DSIP reviews read like advertisements. The moderate but meaningful improvement you describe is exactly what I experienced as well. I think the community benefits more from realistic reports like this than from overhyped claims.

4
Charlie HarrisonDEMO·about 1 month ago

Question for you: did you get bloodwork done before and during your DSIP protocol? I am about to start and trying to decide which panels to run. Obviously the basics but curious if there are any specific markers that are particularly informative for tracking DSIP response.

5
Casey HunterDEMO·about 1 month ago

I ran DSIP at a slightly higher dose than what you used and found the results were actually about the same. This lines up with the dose-response data suggesting there is a ceiling effect. Higher dose just meant more injection site irritation without additional benefit. Your approach seems well-calibrated.

2

Sign in to comment.